Table 1.
Participant characteristics by first- and second-line ART receipt
| Characteristics | Overall (n = 4938) | First-line ART (n = 4067) | Second-line ART (n = 871) | p-value first- vs second-line ART |
|---|---|---|---|---|
| Age, median (IQR) | 36 (30–43) | 36 (30–42) | 40 (34–45) | < 0.001 |
| Male, n (%) | 2587 (52) | 2018 (50) | 569 (65) | < 0.001 |
| CD4+ count/mm3 at respective ART initiation, median (IQR) | 201 (107–298) | 184 (97–265) | 313 (182–506) | < 0.001 |
| Urban residence, n (%) | 3408 (69) | 2874 (71) | 534 (62) | < 0.001 |
| Follow-up duration (months), median (IQR) | 13 (5–23) | 12 (4–25) | 15 (11–18) | < 0.001 |
| Prior TB | 53 (1) | 27 (1) | 26 (3) | < 0.001 |
| Incident TB, n (%) | 248 (5) | 231 (6) | 17 (2) | < 0.001 |
| Died, n (%) | 288 (6) | 270 (7) | 18 (2) | < 0.001 |
| Lost to follow-up, n (%) | 621 (13) | 565 (14) | 56 (6) | < 0.001 |
ART Antiretroviral therapy, IQR Interquartile range, n – frequency